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Abstract Epigenetic mechanisms are thought to play a
major role in the pathogenesis of the major psychoses
(schizophrenia and bipolar disorder), and they may be the
link between the environment and the genome in the
pathogenesis of these disorders. This paper discusses the
role of epigenetics in the management of major psychosis:
(1) the role of epigenetic drugs in treating these disorders.
At present, there are three categories of epigenetic drugs
that are being actively investigated for their ability to treat
psychosis: drugs inhibiting histone deacetylation; drugs
decreasing DNA methylation; and drugs targeting micro-
RNAs; and (2) the role of epigenetic mechanisms in




Major psychoses (which refer chiefly to schizophrenia and
bipolar disorder) are common, chronic, and recurring
mental disorders. Schizophrenia is characterized by im-
paired social and occupational functioning and manifests as
a wide range of abnormalities in perceptual, emotional,
cognitive, and motor processes that cluster in three
categories (Lewis and Sweet 2009): (1) positive symptoms
which include delusions, perceptual disturbances and
hallucinations, and abnormalities in the form of thought.
(2) Negative symptoms which include asociality, avolition
(impaired initiative, motivation and decision making),
mood disturbances, alogia (poverty in the amount or
content of speech), and anhedonia (reduced capacity to
experience pleasure). (3) Cognitive abnormalities like
impairment of memory and selective attention. Bipolar
disorder is a mood disorder characterized by episodes of
mania (extremely elevated mood, energy, unusual thought
patterns, and sometimes psychosis) and depression. Schizo-
phrenia and bipolar disorder each affect about 1% of the
world’s population and cause considerable distress to
affected individuals, emotional burden to their families,
and economic burden to society (Lewis and Sweet 2009;
Martinovich et al. 2009). These disorders are not only a
cause of morbidity, but also increased mortality, which
results from a relatively high rate of suicide and a shorter
life span, due mainly to the medical complications of these
illnesses. The average life expectancy of patients with
schizophrenia and bipolar disorder is 56.3 years (Insel
2009). These disorders are thought to be due to abnormal-
ities involving the development of the brain leading to
disruptions in neural circuits in the brain (Insel 2009).
Family, twin, and adoption studies indicate that major
psychosis has a genetic basis. However, the genetic basis of
major psychosis is known to be complex, involving both
genetic as well as environmental factors (Peedicayil 2010).
Considerable efforts have been put into finding the genetic
mutations and polymorphisms underlying these disorders
by genetic mapping studies. However, to date, no genetic
mutation or polymorphism underlying these disorders has
been definitively identified by these studies (Cyranoski
2010; Peedicayil 2010). Another possibility for the inher-
itance pattern of these disorders involves epigenetics.
Several lines of evidence, in fact, suggest that major
psychosis may be epigenetic disorders (Peedicayil 2007)
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attempting to elucidate the epigenetic basis of these
disorders.
Epigenetic mechanisms in the central nervous system
Epigenetic mechanisms are known to play a major role in
the physiology of the central nervous system (CNS) in
humans. This is not surprising, since epigenetic mecha-
nisms are thought to have played a major role in the
evolution of the human brain (Peedicayil 2001). During the
development of an individual’s CNS, the three major cell
types in the CNS, neurons, and glial cells (astrocytes and
oligodendrocytes), are generated from neural stem cells
(NSC), defined as cells that possess the ability to self renew
and to differentiate into the three major CNS cell types
(Sanosaka et al. 2009). Recent studies have shown that
epigenetic effects, in concert with cues from outside the
NSC, play an important role in regulating the differentiation
potential and fate specification of NSC (Sanosaka et al.
2009; Fig. 1). It is now known that in addition to the
periods of fetal life and childhood, neurogenesis takes place
even during adulthood in the mammalian brain; and even in
neurogenesis during adulthood, epigenetic mechanisms
play an important role (Ma et al. 2010). Epigenetic effects
are also involved in various aspects of neurophysiology-
like cognition (Reichenberg et al. 2009), learning and
memory (Jiang et al. 2008), neuronal plasticity (Borrelli et
al. 2008), chemical neurotransmission (Stadler et al. 2005),
and the circadian clock (Masri and Sassone-Corsi 2010;
Fig. 2). Various epigenetic mechanisms including DNA
methylation and histone modification (Riccio 2010) and
microRNAs (miRNAs; Mehler 2008) are known to play
important roles in CNS physiology. Imprinted genes are
also important in the functioning of the CNS (Davies et al.
2007). They are thought to play an important role in brain
development and behavior, and have been implicated in the
pathogenesis of neurological and mental disorders (Davies
et al. 2007).
Epigenetic abnormalities in major psychosis
Epigenetic abnormalities have been detected in patients
with major psychosis. However, as mentioned by Mill et al.
(2008), at present, it is not clear whether some of these
changes are the cause or the effect of the disease process in
major psychosis. The epigenetic abnormalities in major
psychosis include the following:
Abnormalities involving DNA methylation
Abnormalities of DNA methylation have been the
epigenetic abnormality most studied in major psychosis.
The genes most widely implicated as being abnormally
methylated in major psychosis are the RELN gene which
encodes the glycoprotein reelin, and the GAD1 gene
which encodes the enzyme GAD67. Reelin is an extracel-
lular matrix glycoprotein that guides neurons and radial
glial cells to their positions in the adult brain. GAD67 is
one of two isoforms of glutamic acid decarboxylase, the
enzyme that catalyzes the conversion of the excitatory
neurotransmitter glutamic acid to the inhibitory neuro-
transmitter γ-amino butyric acid (GABA). The promoters
of both the RELN gene (Veldic et al. 2004; Abdolmaleky
et al. 2005;G u i d o t t ie ta l .2007)a n dt h eGAD1 gene
(Veldic et al. 2004;V e l d i ce ta l .2005) have been found to
be hypermethylated in postmortem samples of prefrontal
cortex in patients with schizophrenia and bipolar disorder
due to over-expression of the enzyme DNA methyltrans-
ferase1 (DNMT1), resulting in decreased expression of
reelin and GAD67. Similar results were also found in the
basal ganglia of patients with schizophrenia but not in
patients with bipolar disorder (Veldic et al. 2007). Grayson
(2010) has tried to put these data into perspective by
proposing that an epigenetic dysfunction that perturbs
cortical GABAergic neuron transcription impacts both
GABAergic and glutamatergic signaling at the level of
Fig. 1 Regulation of differentiation potential and fate specification of
neural stem cells by epigenetic effects and external cues
Fig. 2 Epigenetic effects
on various aspects of
neurophysiology
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function (glutamic acid). The glutamatergic hypofunction
could then impact the release of dopamine, a neurotrans-
mitter implicated in the pathogenesis of major psychosis.
I th a sa l s ob e e ns u g g e s t e db yR o t he ta l .( 2009)t h a t
although there is strong evidence for epigenetic abnor-
malities in the RELN and GAD1 genes in major psychosis,
it is unlikely that their epigenetic dysfunction alone
confers susceptibility to psychosis. Instead, it is likely
that many genes are epigenetically dysfunctional in these
disorders.
Another gene for which there is preliminary evidence of
being epigenetically modified leading to the development
of major psychosis is the gene encoding membrane-bound
catechol-O-methyltransferase (MB-COMT; Abdolmaleky et
al. 2006). MB-COMT is one of the two isoforms of COMT,
the enzyme which is involved in the catabolism of the
neurotransmitters dopamine and noradrenaline. Abnormal-
ities in neurotransmission of both these neurotransmitters
have been implicated in the pathogenesis of major
psychosis (Sadock and Sadock 2007). A recent genome-
wide profiling of DNA methylation in patients with
schizophrenia and bipolar disorder found numerous other
genes to be abnormally methylated in these disorders (Mill
et al. 2008). These included the genes encoding brain-
derived growth factor (BDNF) and MARLIN-1, a RNA-
binding protein that is widely expressed in the brain and
that regulates the production of functional GABA-B
receptors. However, the results of this study await confir-
mation and replication.
Abnormalities involving histone modification
Much less work has been done on histone modifications
underlying major psychosis than on abnormalities in
DNA methylation. Akbarian et al. (2005) found that
patients with schizophrenia as a group showed no
alterations in histones as compared to controls. However,
in a subgroup of patients, levels of H3-(methyl) arginine
17 exceeded controls and this was associated with
decreased gene expression. The authors suggested that
histone modifications may contribute to the pathogenesis
of prefrontal dysfunction in schizophrenia. Since that
report on histone modifications in major psychosis, there
have been other reports such as that of Huang et al.
(2007) who showed that chromatin remodeling mecha-
nisms at GABAergic gene promoters occur throughout an
extended period of normal human prefrontal cortex
development and are involved in the pathogenesis of
schizophrenia. More recently, Sharma et al. (2008)
reported that histone deacetylase1 expression is increased
in the prefrontal cortex of patients with schizophrenia,
compared to controls.
Abnormalities involving microRNAs
miRNAs have also been studied in major psychosis, so far
mainly in patients with schizophrenia. The first study to
report abnormal miRNA expression in schizophrenia was
that of Perkins et al. (2007) which compared the expression
of 264 miRNAs in postmortem prefrontal cortex obtained
from 13 patients with schizophrenia and 2 patients with
schizoaffective disorder with that in 21 normal controls.
These authors found that 16 miRNAs were differentially
expressed in the patient group compared with the control
group. More recently, Beveridge et al. (2010) found a
significant increase in global miRNA expression in post-
mortem superior temporal gyrus and the dorsolateral
prefrontal cortex obtained from patients with schizophrenia
as compared to normal controls. The role of miRNAs in
disease pathogenesis has also begun to be investigated in
postmortem brain samples from patients with bipolar
disorder with results suggesting abnormalities of miRNA
expression (Kim et al. 2010; Moreau et al. 2011). The study
of the role of miRNAs in major psychosis is in its very
early stages and needs to be extended, replicated, and
confirmed.
Environmental factors in major psychosis
Environmental factors are thought to be involved in the
pathogenesis of schizophrenia and bipolar disorder (Lewis
and Sweet 2009; Martinovich et al. 2009). It is also now
well established that environmental factors modify epige-
netic mechanisms of gene expression (Liu et al. 2008).
There is evidence that many environmental factors may
influence the pathogenesis of major psychosis by altering
epigenetic mechanisms. These include psychosocial factors,
childhood adversities, migration, urban residence, nutrition,
and advanced paternal age (Peedicayil 2010). The study of
the means by which environmental factors modify epige-
netic mechanisms of gene expression to alter behavior and
lead to the development of mental disorders is a very new
area of research but is likely to be of great relevance and
importance in the future (Rutten and Mill 2009; Peedicayil
2010).
Current management of major psychosis
Currently, there are three major forms of management of
patients with major psychosis. One is the use of psycho-
tropic drugs (drugs whose major effects on the body are to
correct abnormalities which characterize those found in
patients with mental disorders). Another is psychotherapy
which refers to the treatment of emotional problems in
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third major aspect of treatment of major psychosis is
electroconvulsive therapy (ECT), which involves the
administration of a small dose of electricity to the scalp of
the patient in order to produce a major seizure. ECT was
first demonstrated to be useful in the treatment of patients
with mental disorders by the Italian scientists Cerletti and
Bini in 1938 (Payne and Prudic, 2009). Presently, it is most
frequently used to treat patients with severe depressive
episodes and is the most effective treatment for such
patients. To a lesser extent, it is useful to treat patients
with manic episodes and schizophrenia (Payne and Prudic,
2009).
Epigenetic management of major psychosis
Since epigenetic mechanisms are thought to be involved in
the pathogenesis of major psychosis, as discussed above,
correcting the epigenetic abnormalities involved in major
psychosis may lead to clinical improvement of patients with
these disorders. Epigenetic management of major psychosis
comprises the following: epigenetic therapy using drugs
that modify abnormal epigenetic patterns of gene expres-
sion, and epigenetic effects of ECT.
Epigenetic therapy of major psychosis
Epigenetic therapy makes use of drugs to change the
epigenetic patterns of patients to prevent, cure, or
ameliorate disease (Peedicayil 2006; Ptak and Petronis
2008).
Research on the use of epigenetic drugs for a variety of
clinical conditions is an active area of epigenetic research at
present and a few epigenetic drugs have already been
approved for clinical use. Many psychotropic drugs that are
currently in use have been shown to influence epigenetic
mechanisms of gene expression in addition to other
mechanisms of action. The most prominent and best
example of this is the mood stabilizer valproic acid or its
salt, sodium valproate. Valproic acid, which is a short-chain
fatty acid, has been commonly used as an antiepileptic drug
since the late 1960s. It was marketed in France in 1969 but
was not licensed in the USA until 1978 (Porter and
Meldrum 2009). More recently, it was found to have
mood-stabilizing effects in patients with bipolar disorder.
It has some well-established mechanisms of action as an
antiepileptic drug which could contribute to its mood-
stabilizing effect: it prolongs the inactive state of sodium
channels after depolarization; it potentiates the action of
GABA at neuronal synapses where GABA is released, and
it blocks T-type calcium channels in thalamic neurons.
However, in addition to these actions, it is thought to act
epigenetically by inhibiting histone deacetylases (HDACs)
and by also causing demethylation of DNA (Dong et al.
2010). Valproic acid, co-administered with typical and
atypical antipsychotics, has also been shown to be useful
in the management of chronic schizophrenia (Wassef et al.
2000) and treatment-resistant schizophrenia (Kelly et al.
2006). This beneficial effect may be due to activation of
DNA demethylation, leading to reversal of a repressed
nuclear epigenetic state in cortical neurons (Guidotti et al.
2009; 2011).
Fluoxetine, which is an antidepressant that inhibits the
reuptake of serotonin by presynaptic neurons in the
brain, in addition, has also been shown by Cassel et al.
(2006) to induce expression of the methyl-CpG-binding
proteins (MBDs) MeCP2 and MBD1 in normal adult rat
brain after repeated injection for 10 days. Induction of the
MBDs was accompanied by enhanced HDAC2 labeling
intensity and mRNA synthesis and decreased acetylated
forms of histone H3. These effects were found in three
serotonin projection areas: the caudate–putamen, the
frontal cortex, and the dentate gyrus subregion of the
hippocampus. These data suggested to the authors that
GABAergic neurons are major target cells expressing
MeCP2 in response to fluoxetine.
The tricyclic antidepressant imipramine, which is known
to inhibit the reuptake of noradrenaline and serotonin by
presynaptic neurons in the brain, has also been shown to
affect chromatin remodeling. Tsankova et al. (2006)
administered chronic social defeat stress (an animal model
of depression) followed by chronic imipramine to mice and
studied adaptations at the levels of gene expression and
chromatin remodeling of five brain-derived neurotrophic
factor (Bdnf) splice variant mRNAs (I–V) and their unique
promoters in the hippocampus. Defeat stress caused lasting
downregulation of Bdnf transcripts III and IV and robustly
increased repressive histone methylation at their
corresponding promoters. Chronic imipramine administra-
tion reversed this downregulation and increased histone
acetylation at these promoters. The hyperacetylation caused
by imipramine administration was associated with a
selective downregulation of histone deacetylase 5.
miRNAs have also been shown to be affected by
currently used psychotropic drugs. Zhou et al. (2009) found
hippocampal miRNA changes following chronic adminis-
tration of valproic acid and lithium to rats. Lithium, like
valproic acid, is a mood-stabilizing drug. It is the lightest of
the alkali metals and was serendipitously found to have
anti-manic effects in 1949. Lithium carbonate and lithium
chloride are the lithium salts that are commonly used in
clinical practice. The predicted effectors of the miRNAs
affected by valproic acid and lithium are known to be
involved in neurite outgrowth, neurogenesis, and cell
signaling (Zhou et al. 2009). These findings were the first
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targets for the actions of psychotropic drugs. Chen et al.
(2009) showed that there were changes in the expression
patterns of 7 of 13 miRNAs in lymphoblastoid cell lines in
response to lithium treatment. These authors also showed
that there were significant changes in mRNA targets that
inversely correlated with changes in the expression of two
of the miRNAs.
At present, there are three types of epigenetic drugs that
are being investigated for the treatment of major psychosis:
drugs inhibiting HDACs, drugs targeting DNA methyla-
tion, and drugs targeting miRNAs. Trials of epigenetic
drugs in the treatment of major psychosis presently are at
preclinical stages. Epigenetic drugs that are being investi-
gated for such a purpose include SAHA (vorinostat), MS-
275, and phenylbutyrate (Best and Carey 2010; Grayson et
al. 2010).
Drugs inhibiting HDACs
The N-terminal tails of histones are subjected to a variety
of post-translational modifications, one of which is
acetylation of histones, a reaction catalyzed by a group
of histone acetyltransferases. Histones are deacetylated
by a group of HDACs. Most work on the use of
epigenetic drugs in the management of major psychosis
has focused on the use of drugs that inhibit HDACs.
Several classes of these drugs are presently being
investigated for therapeutic use (Peedicayil 2006;P t a k
and Petronis 2008). One of the earliest studies to show the
use of HDAC inhibitors in major psychosis was that of
Tremolizzo et al. (2002)i nw h i c hL-methionine was
administered for 15 days to mice, which resulted in a
marked decrease of reelin and GAD67 mRNAs. This effect
was associated with an increase in the number of
methylated cytosines in the CpG islands of the RELN
promoter. Valproic acid was found to revert the down-
regulation of reelin and GAD67 expression. The same
group later found that valproate, when administered to
mice treated this way, enhanced acetylated histone H3
content and prevented methionine-induced RELN promot-
er hypermethylation, reelin mRNA downregulation, and
behavioral deficits (Tremolizzo et al. 2005). More recent-
ly, it was shown by Simonini et al. (2006) that the
benzamide derivative MS-275 is a potent, long-lasting
brain region-selective HDAC inhibitor. They found that
MS-275 increased the content of acetylhistone 3 (Ac-H3)
in the frontal cortex of mice at a relatively low dose
compared to the doses required for the same effect in
regions of the brain like the hippocampus and the striatum.
M o r e o v e r ,M S - 2 7 5w a sf o u n dt ob eam u c hm o r ep o t e n t
HDAC inhibitor than valproic acid. These authors sug-
gested that benzamide derivative HDAC inhibitors like
MS-275 may express greater efficacy than valproic acid as
adjunctives to antipsychotics in the treatment of major
psychosis.
Covington et al. (2009) showed that chronic social defeat
stress in mice caused a transient decrease, followed by a
persistent increase, in levels of acetylated histone H3 in the
nucleus accumbens, an important limbic region. This
persistent increase in H3 acetylation was associated with
decreased levels of histone deacetylase 2 (HDAC2) in the
nucleus accumbens. These changes in H3 acetylation and
HDAC2 expression were found to mediate long-lasting
positive neuronal adaptations, since infusion of HDAC
inhibitors into the nucleus accumbens exerted robust
antidepressant-like effects in the social defeat stress model
as well as other behavioral tests. The infusion of MS-275
also reversed the effects of chronic social defeat stress on
global patterns of gene expression in the nucleus accum-
bens as determined by microarray analysis, with marked
similarities to the effects of the commonly used antidepres-
sant fluoxetine.
It has also been demonstrated that HDAC inhibition is
linked to DNA demethylation. Dong et al. (2007) admin-
istered L-methionine to mice for seven days and then
measured RELN and GAD1 promoter methylation and
MeCP2 bound to methylated cytosines of the RELN and
GAD1 promoters. Levels of RELN and GAD1 promoter
hypermethylation induced by methionine administration
decreased by about 50% after 6 days of methionine
withdrawal. When valproate or MS-275 was given after
the stopping of methionine administration, these drugs
dramatically accelerated the demethylation of both pro-
moters. The authors showed that valproate and MS-275
increased the binding of acetylhistone-3 to the promoters of
RELN and GAD1genes, suggesting that histone-3 covalent
modifications modulate DNA demethylation in neurons,
supporting the view that directly or indirectly, HDAC
inhibitors may facilitate DNA demethylation.
HDACsbelongtoafamilyofisozymesandinaninteresting
and potentially important study, Guan et al. (2009)f o u n dt h a t
neuron-specific over-expression of HDAC2, but not that of
HDAC1, decreased dendritic spine density, synapse number,
synaptic plasticity, and memory formation. Conversely,
Hdac2 deficiency resulted in increased synapse number and
memory facilitation, similar to what occurs when HDAC
inhibitors are administered chronically to mice. Moreover,
reduced synapse number and learning impairment of
HDAC2-overexpressing mice were decreased by chronic
administration of HDAC inhibitors. It was also found that
treatment with HDAC inhibitors failed to further facilitate
memory formation in Hdac2-deficient mice. Moreover,
analysis of promoter occupancy showed an association of
HDAC2 with the promoters of genes implicated in synaptic
plasticity and memory formation. Based on these results,
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synaptic plasticity and long-lasting changes of neural circuits,
which in turn negatively regulates learning and memory and
that hence HDAC2-selective inhibitors may be useful in
human diseases with memory impairment. As mentioned
above, memory can be impaired in patients with major
psychosis and hence may be usefully treated with such drugs.
Drugs decreasing DNA methylation
DNA methylation is associated with inhibition of gene
transcription and is catalyzed by a family of enzymes called
the DNMTs. At present, several drugs that inhibit the
DNMTs are being investigated for use in clinical practice
(Peedicayil 2006; Ptak and Petronis 2008). DNA is thought
to be demethylated by a putative demethylase (De Carvalho
et al. 2010; Dong et al. 2010).
The first study to investigate the effect of decreasing
DNA methylation with regard to major psychosis was that
of Kundakovic et al. (2007). These authors found, using
cultured NT-2 neuronal precursor cells, that the DNMT
inhibitors doxorubicin, azacytidine, and zebularine
inhibited DNMT1 leading to the activation of human RELN
and GAD1 expression. Later on, Kundakovic et al. (2009)
found that the same DNMT inhibitors inhibited the
DNMTs, DNMT1, DNMT3A, and DNMT3B, leading to
decreased DNA methylation and the reorganization of
chromatin surrounding the regulatory regions of the RELN
and GAD1 genes, which have been found to be epigenet-
ically modified in postmortem brains of patients with
schizophrenia. More recently, Dong et al. (2010) incubated
an Sssl methylated mouse RELN promoter fragment (−720
to +140) with nuclear extracts from the mouse frontal
cortex. They observed DNA demethylating activity which
was increased in frontal cortex nuclear extracts from mice
treated with valproate. They suggested that valproate up-
regulates RELN and GAD1 expression by reducing the
methylation of the promoters of these two genes, and that
the identification of an enzyme in the brain that facilitates
DNA demethylation, and understanding how drugs induce
DNA demethylation, are crucial to progress in the epige-
netic therapy of mental disorders.
Drugs targeting miRNAs
Since, as described above, miRNAs are thought to be
involved in the pathogenesis of the major psychoses, drugs
targeting miRNAs may be useful in the treatment of these
disorders. Dinan (2010) has recently discussed the possible
role of targeting miRNAs in patients with major psychosis.
He suggested that the targeting of miRNAs to treat major
psychosis involves several hurdles relating to delivery,
selectivity, and efficacy, but offers hope as a therapeutic
option in the future. Dinan suggested that there are two
possible methods that can be used to target miRNAs:
inhibiting miRNAs using small molecules, or using smart
technologies to administer double-stranded miRNA mimics
or antagomirs. A crucial first step in the development of
such technologies may be the demonstration that the
centrally administered technology is capable of producing
behavioral changes in animals. Dinan suggested that
evolving technologies employing liposomes, nanoparticles,
and specific nucleotide delivery through cell membrane
targeting may provide the solution for the targeting of
miRNAs in major psychosis. It is apparent from the above
that drug targeting of miRNAs in patients with major
psychosis is well into the future.
Epigenetic effects of electroconvulsive therapy
Tsankova et al. (2004) used chromatin immunoprecipitation
assays to measure in rat hippocampus levels of histones H3
and H4 acetylation and phosphoacetylation at the promoters
of the c-fos, BDNF, and cyclicAMP response element-
binding protein (CREB) genes, the expression of which is
altered by ECT. They found that, with few exceptions,
levels of H4 acetylation correlated with mRNA levels for c-
fos, BDNF, and CREB throughout the acute and chronic
periods of administration of ECT whereas acetylation and
phosphoacetylation of H3 were detected more selectively.
Their results suggested to the authors that the chronic
downregulation of c-fos transcription that they observed
may be achieved at the level of H4 acetylation, whereas
chronic up-regulation of BDNF transcription may be
sustained by control of H3 acetylation selectively at the
BDNF P3 and P4 promoters. These results provided for the
first time in vivo evidence that ECT causes epigenetic
changes in gene expression.
More recently, Ma et al. (2009) employed ECT to study
epigenetic changes that may help explain seizure-induced
up-regulation of adult neurogenesis in mouse hippocampal
neurons. They focused on Gadd45b, a gene belonging to
the Gadd45 family and which encodes a protein product,
Gadd45b, which links neuronal circuit activity to region-
specific DNA demethylation and expression of paracrine
neurogenic niche factors from mature neurons in control-
ling key aspects of activity-dependent adult neurogenesis.
They found that ECT-dependent induction of Gadd45b
promotes DNA demethylation and adult neurogenesis in
mice hippocampal neurons. The results of these two studies
suggest that at least a part of the mechanism of action of
ECT in patients with major psychosis may be by altering
epigenetic mechanisms of gene expression in the brain. The
precise role of epigenetic changes induced by ECT in the
management of major psychosis may be a good topic for
future research.
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Epigenetics plays a major role in the pathogenesis of the
major psychoses. Although at present there are some leads
on the epigenetic abnormalities underlying these disorders,
the precise epigenetic basis for the pathogenesis of these
disorders awaits elucidation The elucidation of the epige-
netic abnormalities underlying major psychosis will help in
the understanding of the mechanisms by which epigenetic
drugs and ECT help in the clinical improvement of patients
with these disorders and will help in the development of
more effective and safer epigenetic drugs to treat these
disorders.
At present, a major drawback in the management of
the major psychoses, unlike as in the case of most
medical disorders, is that there are no valid biomarkers to
aid in the diagnosis and treatment of patients with these
disorders. When the epigenetic abnormalities underlying
these disorders have been elucidated, epigenetic bio-
markers (Peedicayil 2008; Mikkelsen et al. 2010)a r e
likely to help in this regard.
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